Melchiorri Anthony J, Bracaglia Laura G, Kimerer Lucas K, Hibino Narutoshi, Fisher John P
1 Fischell Department of Bioengineering, University of Maryland , College Park, Maryland.
2 Department of Surgery & Cardiac Surgery, Johns Hopkins University School of Medicine , Baltimore, Maryland.
Tissue Eng Part C Methods. 2016 Jul;22(7):663-70. doi: 10.1089/ten.TEC.2015.0562. Epub 2016 Jun 17.
A critical challenge to the success of biodegradable vascular grafts is the establishment of a healthy endothelium. To establish this monolayer of endothelial cells (ECs), a variety of techniques have been developed, including cell seeding. Vascular grafts may be seeded with relevant cell types and allowed to mature before implantation. Due to the low proliferative ability of adult ECs and issues with donor site morbidity, there has been increasing interest in using endothelial progenitor cells (EPCs) for vascular healing procedures. In this work, we combined the proliferative and differentiation capabilities of a commercial cell line of early EPCs with an established bioreactor system to support the maturation of cell-seeded vascular grafts. All components of the vascular graft and bioreactor setup are commercially available and allow for complete customization of the scaffold and culturing system. This bioreactor setup enables the control of flow through the graft, imparting fluid shear stress on EPCs and affecting cellular proliferation and differentiation. Grafts cultured with EPCs in the bioreactor system demonstrated greatly increased cell populations and neotissue formation compared with grafts seeded and cultured in a static system. Increased expression of markers for mature endothelial tissues were also observed in bioreactor-cultured EPC-seeded grafts. These findings suggest the distinct advantages of a customizable bioreactor setup for the proliferation and maturation of EPCs. Such a strategy may be beneficial for utilizing EPCs in vascular tissue engineering applications.
可生物降解血管移植物成功的一个关键挑战是建立健康的内皮。为了建立这种内皮细胞(ECs)单层,已经开发了多种技术,包括细胞接种。血管移植物可以接种相关细胞类型,并在植入前使其成熟。由于成年ECs的增殖能力低以及供体部位发病问题,人们越来越关注使用内皮祖细胞(EPCs)进行血管修复手术。在这项工作中,我们将早期EPCs商业细胞系的增殖和分化能力与一个成熟的生物反应器系统相结合,以支持接种细胞的血管移植物的成熟。血管移植物和生物反应器设置的所有组件都可商购,并允许对支架和培养系统进行完全定制。这种生物反应器设置能够控制通过移植物的流动,对EPCs施加流体剪切应力,并影响细胞增殖和分化。与在静态系统中接种和培养的移植物相比,在生物反应器系统中用EPCs培养的移植物显示细胞数量大大增加,新组织形成。在生物反应器培养的接种EPCs的移植物中也观察到成熟内皮组织标志物的表达增加。这些发现表明可定制生物反应器设置对EPCs增殖和成熟具有明显优势。这种策略可能有利于在血管组织工程应用中利用EPCs。